tbuckley/cabot-search huggingface dataset:
Immune Responses to Mouse Neuroblastoma C1300. I. Preliminary Observations on Cell-Mediated Immune Responses 2
Authors: Mildred E. Phillips, Patricia M. Cipuzak, Dennis Della Penta, Melitta Schachner
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Immune Responses to Mouse Neuroblastoma C1300. I. Preliminary Observations on Cell-Mediated Immune Responses Get access Mildred E. Phillips, Mildred E. Phillips 3Department of Pathology, School of Basic Health Sciences, Health Sciences Center, State University of New York, Stony Brook, N.Y. 11794. Search for other works by this author on: Oxford Academic PubMed Google Scholar Patricia M. Cipuzak, Patricia M. Cipuzak 3Department of Pathology, School of Basic Health Sciences, Health Sciences Center, State University of New York, Stony Brook, N.Y. 11794. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dennis Della Penta, Dennis Della Penta 3Department of Pathology, School of Basic Health Sciences, Health Sciences Center, State University of New York, Stony Brook, N.Y. 11794. Search for other works by this author on: Oxford Academic PubMed Google Scholar Melitta Schachner Melitta Schachner 4Children's Hospital Medical Center, 300 Longwood Ave., Boston, Mass. 02115. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 4, October 1977, Pages 1215–1219, https://doi.org/10.1093/jnci/59.4.1215 Published: 01 October 1977 Article history Received: 04 November 1976 Accepted: 07 April 1977 Published: 01 October 1977
Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation
Authors: U. R. Popat, R. Saliba, C. Hosing, I. Khouri, A. M. Alousi, S. A. Giralt, M. J. de Lima, M. H. Qazilbash, R. Champlin, P. Anderlini
Journal: Journal of Clinical Oncology (2009)

e19507 Background: Age at diagnosis is a poor prognostic factor for overall survival after standard therapy for HD. Whether older age is a prognostic factor for outcome after autologous transplantation is not known. We sought to evaluate the effect of older age at diagnosis on transplant outcome. Patients and Methods: All patients with HD undergoing autologous transplantation with BEAM conditioning (BCNU, Etoposide, Cytarabine, and Melphalan) between January 1996 and December 2007 were included in this study. During these 12 years, 248 patients (103 males) underwent autologous transplantation. Seventy two patients (29%) were older than 40 years of age at the time of initial diagnosis. Median age at transplantation was 31 years (range 11–74). At transplantation, 63 (25%) were in complete remission (CR); 148 (60%) were in partial remission (PR); and 37 (15%) had stable (SD) or progressive disease (PD). Forty-six patients (19%) had received more than 3 courses of chemotherapy prior to transplantation. LDH was elevated in 131 (53%). Peripheral blood stem cells were used as stem cell source in 241 (97%) patients. Results: With a median follow up of 48 months (range, 1–143 months), the 48-month overall (OS) and event-free survival (EFS) were 72% (95% CI; 65%-77%) and 57% (95% CI; 50%-63%), respectively. The cumulative incidence of non-relapse mortality at 1 year was 1.6%. The cumulative incidence of secondary MDS or AML was 8%. In univariate analysis, disease status (p&lt;0.001) and number of prior chemotherapy regimens (p=0.007) were the only factors significantly predicting OS. Disease status was the only factor significant (p&lt;0.01) in a multivariate analysis with a hazard ratio of 2.7 (1.1–6.9) and 9.2 (3.4–25) for patients in PR, and SD/PD respectively (CR reference group). Age at diagnosis was not a significant factor (see table ). Conclusions: High-dose chemotherapy and autologous transplantation abrogate the adverse impact of age at diagnosis in patients with HD. [Table: see text] No significant financial relationships to disclose.
Apoptosis Resistance of Blood Cells From Patients With Paroxysmal Nocturnal Hemoglobinuria, Aplastic Anemia, and Myelodysplastic Syndrome
Authors: Kentaro Horikawa, Hideki Nakakuma, Tatsuya Kawaguchi, Norihiro Iwamoto, Shoichi Nagakura, Tadashi Kagimoto, Kiyoshi Takatsuki
Journal: Blood (1997)
Complications of Radioactive Iodine Treatment of Thyroid Carcinoma
Authors: Stephanie L. Lee
Journal: Journal of the National Comprehensive Cancer Network (2010)

Radioactive iodine (RAI) in the form of 131 I has been used to treat thyroid cancer since 1946. RAI is used after thyroidectomy to ablate the residual normal thyroid remnant, as adjuvant therapy, and to treat thyroid cancer metastases. Although the benefits of using RAI in low-risk patients with thyroid cancer are debated, it is frequently used in most patients with thyroid cancer and is clearly associated with acute and long-term risks and side effects. Acute risks associated with RAI therapy include nausea and vomiting, ageusia (loss of taste), salivary gland swelling, and pain. Longer-term complications include recurrent sialoadenitis associated with xerostomia, mouth pain, dental caries, pulmonary fibrosis, nasolacrimal outflow obstruction, and second primary malignancies. This article summarizes the common complications of RAI and methods to prevent and manage these complications.
Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Christoph Ochs, Philipp Hemmati, Giang Lam Vuong, Kathrin Rieger, Olga Blau, Jörg Westermann, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na
Journal: Blood (2013)
Short-Term Fluctuations and Long-Term Trends in Anchorage-Independent Multiplication Among Cryopreserved Subpopulations of a Spontaneously Transformed Balb/3T3 Clone&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: H Rubin, B Chu, C Romerdahl
Journal: JNCI Journal of the National Cancer Institute (1985)

A spontaneously transformed clone of Balb/3T3 cells which produced primitive pleomorphic sarcomas in nude mice was maintained in serial passage without cryopreservation. It was also cryopreserved at an early passage and thawed out at four successive intervals. The capacity of these 5 subpopulations to form colonies while suspended in agar (CFEag) was assayed repeatedly over a period of almost 3 years. The initial CFEag and the subsequent pattern of change were unique for each of the subpopulations. When later passages of the nonfrozen subpopulation were cryopreserved and then thawed, there was only a slight change in CFEag and colony size in agar. There were differences in multiplication rates of 3 of the subpopulations on plastic surfaces in the same rank order as their CFEag, but the differences were smaller. Short-term fluctuations in CFEag, however, were not paralleled by changes in multiplication rate on plastic. The nonfrozen subpopulation assumed the appearance of nontransformed fibroblasts when crowded for several days on plastic, and these "normalized" cells had a greatly reduced CFEag when assayed in agar. Neither the change in appearance nor the decrease in CFEag with prolonged incubation of crowded cells occurred with one of the cryopreserved subpopulations which had the same CFEag and growth rate on plastic as the nonfrozen subpopulation under optimal conditions. The evidence favors an epigenetic rather than a genetic origin of the variations in appearance and behavior of the subpopulations.
Abstract #4707: RAD001 (everolimus) synergizes with ZD1839 (gefitinib) in NSCLC cells resistant to EGFR-TKI
Authors: Song Dong, Yi-Long Wu, Jian-Quan zhu, She-Juan An, Xu-Chao Zhang, Ai-Lin Guo
Journal: Cancer Research (2009)

Introduction:  EGFR-TKI is one of the most important treatments of NSCLC patients, but not all patients benefited from this due to primary or acquired resistance. This is often due to the activation of alternative signaling pathway. The combination of different signaling pathway inhibitors is a promising strategy. We used the mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) in combination with ZD1839 (gefitinib) on NSCLC cells resistant to EGFR-TKI in vitro and analyzed the molecular mechanism underlying this combination.  Methods:  RAD001 and ZD1839, alone or in combination, were given in vitro to A549 (EGFR Wt) and H1975 (T790M L858R) cell lines and the effects were evaluated by using cell proliferation assay,cell apoptosis assay and western blotting.  Results:  The combination index (CI) of H1975 diminished with the increasing dose of RAD001. When combined with 10\#956;M ZD1839, the CI value  1 when the dose increased to 10\#956;M. And additive effect was observed in A549 cell line. We observed no synergism in the sequential treatment of both cell lines.RAD001 increased the phosphorylation of Akt and inhibited phosphorylation of mTOR, raptor and P70S6K with the dose of 0.5\#956;M,but at least 5\#956;M ZD1839 can inhibited these.  Conclusion:  Our data revealed that combination of RAD001 with ZD1839 exhibited dose-dependent synergism in H1975 and additive effect in A549. This will provide the preclinical rationale for the use of RAD001 to enhance response to ZD1839 in EGFR-TKI resistance patients.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4707.
Comparative Pathology of Cardiac Neoplasms in Humans and in Laboratory Rodents: A Review
Authors: C Hoch-Ligeti, C Restrepo, H L Stewart
Journal: JNCI Journal of the National Cancer Institute (1986)

This review deals with the frequency, heredity, and morphology of 19 different histologic types of cardiac tumors that may affect humans, rat, mouse, guinea pig, and mastomys. Chemicals, durable fibrous materials, viruses, and probably irradiation have induced cardiac tumors in rodents. Apart from the involvement of asbestos in the induction of pericardial mesothelioma, no carcinogens have been identified in induction or promotion of cardiac tumors in humans. A hereditary tendency for the occurrence of myxoma and aortic paraganglioma has been indicated in humans as well as strain-specific heredity for rhabdomyoma in the guinea pig and for atriocaval node tumor in the rat.
Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study
Authors: Firas Abdollah, Jesse D Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S Kibel, Paul L Nguyen, Toni K Choueiri, Kathy J Selvaggi, Mani Menon, Quoc-Dien Trinh
Journal: Journal of the National Comprehensive Cancer Network (2015)

To examine racial disparities in end-of-life (EOL) care among black and white patients dying of prostate cancer (PCa).Relying on the SEER-Medicare database, 3789 patients who died of metastatic PCa between 1999 and 2009 were identified. Information was assessed regarding diagnostic care, therapeutic interventions, hospitalizations, intensive care unit (ICU) admissions, and emergency department visits in the last 12 months, 3 months, and 1 month of life. Logistic regression tested the relationship between race and the receipt of diagnostic care, therapeutic interventions, and high-intensity EOL care.Overall, 729 patients (19.24%) were black. In the 12-months preceding death, laboratory tests (odds ratio [OR], 0.51; 95% CI, 0.36-0.72), prostate-specific antigen test (OR, 0.54; 95% CI, 0.43-0.67), cystourethroscopy (OR, 0.71; 95% CI, 0.56-0.90), imaging procedure (OR, 0.58; 95% CI, 0.41-0.81), hormonal therapy (OR, 0.53; 95% CI, 0.44-0.65), chemotherapy (OR, 0.59; 95% CI, 0.48-0.72), radiotherapy (OR, 0.74; 95% CI, 0.61-0.90), and office visit (OR, 0.38; 95% CI, 0.28-0.50) were less frequent in black versus white patients. Conversely, high-intensity EOL care, such as ICU admission (OR, 1.27; 95% CI, 1.04-1.58), inpatient admission (OR, 1.49; 95% CI, 1.09-2.05), and cardiopulmonary resuscitation (OR, 1.72; 95% CI, 1.40-2.11), was more frequent in black versus white patients. Similar trends for EOL care were observed at 3-month and 1-month end points.Although diagnostic and therapeutic interventions are less frequent in black patients with end-stage PCa, the rate of high-intensity and aggressive EOL care is higher in these individuals. These disparities may indicate that race plays an important role in the quality of care for men with end-stage PCa.
My Bioethics Will Be Intersectional or It Will Be [Bleep]
Authors: Patrick R. Grzanka, Jenny Dyck Brian, Janet K. Shim
Journal: The American Journal of Bioethics (2016)

Danis, Wilson, and White (2016) argue that bioethicists have been glaringly absent from ongoing social movements to combat racism, particularly the institutional and systematic oppression of Africa...
DART - A phase I safety and dose-finding study of the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumors
Authors: M. McKeage, P. Fong, M. Jeffery, M. Ravic, M. B. Jameson
Journal: Journal of Clinical Oncology (2005)

3081 Background: DMXAA (AS1404) targets established tumor vasculature and induces hemorrhagic necrosis of the hypoxic central region of tumors. The drug causes damage to endothelial cells and apoptosis, resulting in exposure of basement membrane, aggregation and activation of platelets and release of vasoactive mediators, leading to capillary rupture, extravasation of contents and cessation of blood flow. In previous phase I studies, DMXAA was well tolerated across a wide range of doses; QTc prolongation and ocular effects were documented. This study was designed to confirm the safety profile and identify suitable doses of DMXAA for further trials. Methods: Using a crossover design, 15 patients with refractory tumors were allocated randomly to receive 6 sequential doses of DMXAA (300, 600, 1200, 1800, 2400 and 3000 mg m−2), each given once weekly as a 20-min iv infusion. Clinical and laboratory analyses were performed regularly, including extensive ECG and ophthalmic measurements. Tumor blood flow parameters were assessed by DCE-MRI. Results: 14 patients completed the study, each receiving 6 doses of DMXAA. The drug was generally well tolerated. Transient, moderate increases in the heart rate-corrected cardiac QT (QTc) interval occurred at the two highest doses. DMXAA produced transient dose-dependent increases in blood pressure. Transient visual disturbances occurred at the two highest dose levels. Ve, a DCE-MRI parameter indicative of vascular permeability, increased significantly after DMXAA, while no significant changes were observed in other blood flow parameters. Plasma levels of the vascular damage biomarker 5-hydroxyindoleacetic acid (5-HIAA) increased in the 4 hours after treatment in a dose-dependent fashion, with a plateau around 1200mg m−2. Conclusions: Doses in the range of 1200 mg m−2 have been selected for further studies (a program of phase II combination studies with taxanes and platins has now begun) because this dose produced no significant effect on the QTc interval, produced near maximum plasma concentrations of 5-HIAA and was well tolerated. DCE-MRI findings were consistent with increased vascular permeability after DMXAA. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Antisoma Antisoma
Retinal Nerve Fiber Layer Loss in Patients With Type 2 Diabetes and Diabetic Neuropathy
Authors: Hae-Young Lopilly Park, Juyoung Shin, Jae Hyung Lee, Chan Kee Park
Journal: Diabetes Care (2016)

Retinal nerve fiber layer (RNFL) loss is commonly observed in patients with diabetes and has correlations with the stage of diabetic retinopathy (DR) (1). However, several reports have shown RNFL loss in patients with diabetes independent of DR, suggesting that the function of neuronal cells in the retina is compromised even before the appearance of overt microvascular changes (2–4). We hypothesized that RNFL loss in patients with diabetes without overt DR may represent a distinct type of diabetic neuropathy. Analyses of the status of peripheral neuropathy and cardiac autonomic neuropathy (CAN) were compared according to the location (superior or inferior) of RNFL loss in patients with type 2 diabetes without DR.

We performed a retrospective review of all patients with type 2 diabetes who underwent assessment of …
P1234 : Low hepcidin/ferritin ratio in C282Y homozygotes correlates inversely with transferrin saturation and non-transferrin bound iron levels
Authors: J.D. Ryan, E. Ryan, J. Russell, B. Coughlan, H. Tjalsma, D.W. Swinkels, S. Stewart, J. Crowe
Journal: Journal of Hepatology (2015)
Self-report measures in athletic preparation
Authors: Anna E Saw
Journal: British Journal of Sports Medicine (2016)

I investigated athlete self-report measures1 (ASRM)—paper based or electronic records of an athlete's perceived physical, psychological and/or social well-being, completed on a regular (often daily) basis.⇓



Anna Saw



I aimed to determine: (1) if ASRM are valuable to athletic preparation and, if so, (2) how their use may be optimised.

Modern sport invests substantial human and financial resources into athlete monitoring innovations in order to optimise athlete performance and avoid negative outcomes such as injury. However, the drive to gain a competitive advantage has led to the early adoption of various monitoring methods prior to establishing a proof of concept or validity and reliability. …
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
Authors: Ryan Bruce Corcoran, Chloe Evelyn Atreya, Gerald Steven Falchook, Jeffrey R. Infante, Omid Hamid, Wells A. Messersmith, Adil Daud, Eunice Lee Kwak, David Ryan, Razelle Kurzrock, Peng Sun, Elizabeth Ann Cunningham, Keith W. Orford, Monica Motwani, Yuchen Bai, Kiran Patel, Alan P. Venook, Scott Kopetz
Journal: Journal of Clinical Oncology (2014)

3517 Background: BRAF V600 mutations occur in 5-15% of metastatic CRC and predict poor prognosis. Although highly effective in BRAF mutant melanoma, BRAF inhibitor monotherapy has shown poor efficacy in BRAF mutant CRC. Preclinical data suggest that improved MAPK pathway suppression with combined inhibition of BRAF and MEK may improve efficacy. Methods: 43 patients (pts) with BRAF V600 mutant stage IV CRC were treated with D (150mg BID) and T (2mg QD), 17 of whom were enrolled in a pharmacodynamic cohort with tumor biopsies pre-treatment and after 2 weeks of therapy. Archival tissues were analyzed for microsatellite instability (MSI), PTEN loss, and 487-gene sequencing (Illumina). Results: Of 43 pts, 5 (12%) achieved partial response (PR) or better (with or without confirmation), including 1 (2%) pt with complete response (CR) ongoing >22 months. An additional 22 (51%) pts achieved stable disease (SD) at first restaging, of which 11 (26%) pts had a minor response (10% to 30% tumor reduction). 10 (23%) pts remained on study >6 months. All 9 evaluable post-dose biopsies had reduced levels of phospho-ERK relative to pre-dose (average decrease 47% ±24), however, the % pERK inhibition and response did not correlate proportionally. Mutational analysis of 15 subjects has been completed to date. The pt with CR and 2 of 3 evaluable pts with PR had PIK3CA mutation. Neither PTEN loss nor MSI correlated with efficacy. Conclusions: The combination of D + T has activity in a subset of BRAF V600 mutant CRC pts, with several PRs and a durable CR. MAPK signaling was inhibited in all pts evaluated, but to a lesser degree than observed in BRAF mutant melanoma with D as a single agent. PIK3CA mutations were identified in responding patients and thus do not preclude response to this regimen, but a definitive correlation between PIK3CA mutations and efficacy cannot be established given the limited pt sample. Biomarker refinement and additional therapeutic combinations may improve clinical activity. Clinical trial information: IND No: 113,557.
Costs of hospitalization for head and neck (HNC) or non-small cell lung cancer (NSCLC) patients (Pts) with oral mucositis (OM) and/or esophagitis who undergo radiochemotherapy
Authors: K. R. Carson, K. R. McCaffrey, R. Sharma, G. J. Okano, A. Argiris, A. S. Pickard, G. T. Schumock, C. L. Bennett
Journal: Journal of Clinical Oncology (2005)

8089 Background: OM/esophagitis is a significant toxicity associated with chemoradiotherapy treatment of HNC and NSCLC. In severe cases, hospitalization for intravenous nutrition and pain control is necessary. The Northwestern University Cost of Cancer Project conducted one of the first studies of the direct costs of this toxicity. The objective of this study was to compare the costs of hospitalization in HNC and NSCLC patients who experience OM/esophagitis to those who do not report this toxic side effect. Methods: Medical records for HNC or NSCLC patients who received care at an NCI-designated comprehensive cancer center were reviewed for information on demographics, disease and stage, treatment, and medical resource use. Hospital costs were estimated at $1500 per day, based on prior studies at our institution. In total, 200 charts will be reviewed for this study, with the preliminary results from 73 patients being reported here. Results: Of the 73 patients, 45 (62%) had HNC and 28 (38%) had NSCLC. Patients with or without OM/esophagitis were similar with respect to sociodemographic and clinical characteristics. However, resource utilization and estimated costs were markedly greater among patients with OM/esophagitis (Table). Median inpatient hospitalization stays and estimated costs for patients with OM/esophagitis (n=52) were 11 days longer and $16,500 greater compared to patients without OM/esophagitis (n=21). Conclusion: Inpatient hospitalization cost estimates for OM/esophagitis in HNC and NSCLC patients are markedly greater than for patients who do not experience OM/esophagitis. Therapies that reduce the incidence and/or severity of OM/esophagitis have the potential to reduce costs through decreased hospitalization. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen
High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias
Authors: D C Betticher, M F Fey, A von Rohr, A Tobler, H Jenzer, A Gratwohl, A Lohri, P Pugin, U Hess, O Pagani
Journal: Annals of Oncology (1994)